Skip to main content
Cancers logoLink to Cancers
. 2021 May 31;13(11):2722. doi: 10.3390/cancers13112722

Non-Invasive Biomarkers for Earlier Detection of Pancreatic Cancer—A Comprehensive Review

Greta Brezgyte 1,, Vinay Shah 1,, Daria Jach 1, Tatjana Crnogorac-Jurcevic 1,*
Editor: Adam E Frampton1
PMCID: PMC8198035  PMID: 34072842

Abstract

Simple Summary

Pancreatic ductal adenocarcinoma (PDAC), which represents approximately 90% of all pancreatic cancers, is an extremely aggressive and lethal disease. It is considered a silent killer due to a largely asymptomatic course and late clinical presentation. Earlier detection of the disease would likely have a great impact on changing the currently poor survival figures for this malignancy. In this comprehensive review, we assessed over 4000 reports on non-invasive PDAC biomarkers in the last decade. Applying the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool, we selected and reviewed in more detail 49 relevant studies reporting on the most promising candidate biomarkers. In addition, we also highlight the present challenges and complexities of translating novel biomarkers into clinical use.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) carries a deadly diagnosis, due in large part to delayed presentation when the disease is already at an advanced stage. CA19-9 is currently the most commonly utilized biomarker for PDAC; however, it lacks the necessary accuracy to detect precursor lesions or stage I PDAC. Novel biomarkers that could detect this malignancy with improved sensitivity (SN) and specificity (SP) would likely result in more curative resections and more effective therapeutic interventions, changing thus the present dismal survival figures. The aim of this study was to systematically and comprehensively review the scientific literature on non-invasive biomarkers in biofluids such as blood, urine and saliva that were attempting earlier PDAC detection. The search performed covered a period of 10 years (January 2010—August 2020). Data were extracted using keywords search in the three databases: MEDLINE, Web of Science and Embase. The Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool was applied for study selection based on establishing the risk of bias and applicability concerns in Patient Selection, Index test (biomarker assay) and Reference Standard (standard-of-care diagnostic test). Out of initially over 4000 published reports, 49 relevant studies were selected and reviewed in more detail. In addition, we discuss the present challenges and complexities in the path of translating the discovered biomarkers into the clinical setting. Our systematic review highlighted several promising biomarkers that could, either alone or in combination with CA19-9, potentially improve earlier detection of PDAC. Overall, reviewed biomarker studies should aim to improve methodological and reporting quality, and novel candidate biomarkers should be investigated further in order to demonstrate their clinical usefulness. However, challenges and complexities in the path of translating the discovered biomarkers from the research laboratory to the clinical setting remain and would have to be addressed before a more realistic breakthrough in earlier detection of PDAC is achieved.

Keywords: pancreatic ductal adenocarcinoma, systematic review, biomarkers, QUADAS-2, early detection, non-invasive

1. Introduction

Pancreatic ductal adenocarcinoma (PDAC), which represents approximately 90% of all pancreatic cancers, is an extremely aggressive disease and one of the most lethal cancers. Its incidence almost equals its mortality, and it has a 5-year survival of only around 9% [1,2]. It caused 7800 deaths in the United Kingdom (UK) in 2018 alone, and, according to GLOBOCAN, there were 458,918 new cases of pancreatic cancer and 432,242 pancreatic cancer-related deaths worldwide in the same year [3]. Furthermore, PDAC incidence is steadily increasing [4,5,6,7].

PDAC is considered a silent killer due to a largely asymptomatic course, late clinical presentation, and rapid progression [8], with fewer than 20% of PDAC patients being diagnosed at early, resectable stages I and II [9,10]. Importantly, if PDAC is detected when still a localized disease, the 5-year survival is around 32% [11], but it can approach 70% following resection of incidentally diagnosed stage I tumors [12,13,14]. It is estimated that it takes at least 10 years between initiating mutation and the birth of parental founder [15]; combined with an increased PDAC incidence with age [5], resectable PDAC has likely already been growing for a number of years. We therefore further on use the term “earlier” rather than “early” stage.

To date, there exists no reliable, non-invasive screening test, either molecular or imaging-based, that will allow accurate PDAC detection at an earlier stage in asymptomatic patients. The conventional methods such as computerized tomography, magnetic resonance imaging or endoscopic ultrasonography are expensive and have low sensitivity (SN) and specificity (SP) for detection of small premalignant lesions [16]. Furthermore, the deep anatomic location of the pancreas makes detection of small-localized tumors unlikely during a routine abdominal examination [17].

In contrast, testing for biomarkers in body fluids such as serum, plasma, urine or saliva is minimally invasive, relatively inexpensive and could allow for earlier PDAC diagnosis [18]. The current gold-standard serum biomarker for PDAC is carbohydrate antigen 19-9 (CA19-9), also known as sialylated Lewis (a) antigen. It is a product of exocrine epithelial cells and various mucins secreted by PDAC cells that are normally found on the surface of erythrocytes [19]. The test was approved by the U.S. Food and Drug Administration (FDA) in 2002 [20]. However, it is recommended to be used only for disease monitoring and prognosis, since the performance of CA19-9 as a diagnostic biomarker is limited by poor SN, false-negative results in the individuals with Lewis negative phenotype and increased false positivity in several benign and malignant biliary disorders [21]. Furthermore, CA19-9 is not recommended as a screening marker due to its low positive predictive value (0.5–0.9%) [22,23,24].

The accuracy of any tumor biomarkers assay, including CA19-9, is linked to the concept of threshold, or cut-off [25]. The CA19-9 cut-off values differ significantly between studies due to the lack of an international standard for CA19-9 and the difference in the assay design and instrument utilized [26]. When the two most frequently used assays for measuring CA19-9, Abbott Architect CA 19-9XR and Roche Elecsys CA19-9, were compared, despite being based on the same monoclonal antibody 1116-NS-19-9 [27], the Abbott assay measured significantly lower CA19-9 values than the Roche one in healthy and benign cases [28]. While the upper reference limit of 37 U/mL, reaching mean SN and SP of 81% and 90%, respectively, as first reported by Steinberg [29], is still able to sufficiently differentiate between controls and PDAC, the CA19-9 values obtained by different methods should not be used interchangeably, the method utilized should be clearly stated and the patients should be monitored using the same assay [28,30]. Thus, despite its role as the principle serological test for PDAC, the standardization of the laboratory testing and correct interpretation of high serum CA19-9 levels with the adequately established cut off has not yet been achieved [31]. The search for a new non-invasive PDAC biomarker with superior SN and SP to CA19-9, which will be easily identifiable and robustly measured in a fully standardized fashion in biofluids, is therefore being actively pursued.

Recent advances in molecular techniques have empowered the discovery of novel biomarkers for earlier detection of PDAC, resulting in a significant and constantly growing body of literature. Despite the discovery of thousands of biomarkers, relatively few have been adequately tested and validated, making the assessment of their potential challenging [32]. This sparked an EDRN (The Early Detection Research Network) workshop at National Cancer Institute (NCI) in 2016, where a selection of the most promising studies was reported [33]. A comprehensive update and critically appraised resource of information on potentially useful novel biomarkers for PDAC is, however, needed.

In the present study, we reviewed over 4000 articles and further assessed 49 published studies from the last decade describing biomarkers in serum, plasma, urine and saliva for earlier PDAC detection, in conjunction with serum CA 19-9, when available. We utilized the Quality Assessment of Diagnostic Accuracy Studies tool (QUADAS-2) to assess the quality of the selected studies and highlighted their potential clinical utility and limitations for earlier PDAC detection.

2. Methods

Two of the authors (G.B. and V.S.) independently conducted a systematic search of MEDLINE, Web of Science and Embase and assessed all the articles published between January 2010 and August 2020. A robust reproducible search strategy was created which utilized the MESH terms “Pancreas OR Pancreatic” AND “Ductal Adenocarcinoma OR PDAC OR Cancer OR Malignancy OR Adenocarcinoma OR Tumour OR Tumor” AND “Liquid Biopsy OR Biomarkers OR Screening OR Stool OR Markers OR Marker OR Urine OR Saliva OR Blood OR Non-invasive OR Non Invasive OR Fluid Biopsy OR Fluid Phase Biopsy OR Detection OR Diagnosis OR Diagnose OR Screen” to search for the potential biomarkers specific for this disease. The filters were adjusted to show the results for studies in the English language only. The article type was set to only include clinical and observational studies in Medline. In Medline and Embase, titles and abstracts were searched. In Web of Science, only titles were searched. PRISMA guidelines were used to assist in the structuring of this systematic review [34]. The inclusion and exclusion criteria for selecting the studies are listed in Table 1.

Table 1.

Inclusion and Exclusion Criteria for study selection.

Inclusion Criteria
1. Pancreatic Ductal Adenocarcinoma
2. Non-invasive method of obtaining a liquid biopsy e.g., plasma, serum, urine, saliva, stool
3. Original data with reported AUC, SN and SP of a proposed biomarker
4. Human studies
5. Manuscripts from January 2010 until August 2020
Exclusion Criteria
1. No specification of what type of pancreatic cancer it was
2. Invasive procedures to obtain the biomarker e.g., tissue biopsy
3. No recorded data either of SN, SP and/or AUC for the tested biomarker
4. Biomarker used for a purpose other than detection e.g., prognostic biomarkers
5. Abstracts, Conference reports/writings, NHS reports, Review Articles

Abbreviations: AUC—Area Under the ROC (Receiver Operating Characteristic) Curve, SN—Sensitivity, SP—Specificity, NHS—National Health Service in UK.

Assessment of the methodological quality of reviewed articles was performed according to QUADAS-2, a validated quality assessment tool commonly used to assess the methodology of investigated studies, and as a measure to improve diagnostic accuracy [35]. With QUADAS-2, we were able to appraise three key domains, namely Patient Selection, Index Test and Reference Standard, for both risk of bias and applicability. For the Patients selection, we assessed if the sample groups were well described and if patient spectrum was representative of the disease. We also assessed if the selection of the controls was appropriate, i.e., if, in addition to healthy controls, samples collected from patients with benign pancreatic diseases at risk for progressing to PDAC were also included. Within the Applicability concerns, we assessed if the data for PDAC stages I/II were reported, as we were aiming to review biomarkers for earlier detection of PDAC. For the Index test (biomarker assay), we appraised how well the assay was described and executed and the results interpreted (SN/SP/AUC with 95% confidence intervals (CIs)) and if the data were split into training and validation sets. To increase the validity of the results, QUADAS-2 also recommends that researchers do not know which study group each patient belongs to (“blinding”) in order to reduce the effects of any foreknowledge in the interpretation of the biomarker assay results [36]. QUADAS-2 includes the need to specify a threshold value for the Index test prior to obtaining the results; however, this is not suitable for newly discovered biomarkers, where one of the aims is to determine the appropriate cut-offs with regards to the SN, SP and AUC. For the Reference Standard, we assessed if the study specifies that PDAC diagnosis was confirmed by histology and if the staging was pathological or clinical. However, as biomarker discovery studies are typically performed on retrospectively collected samples with an already established diagnosis, we additionally included a comparison of the new biomarker with CA19-9. Flow and Timing were excluded from our QUADAS-2 scoring, as it was difficult to assess this parameter, i.e., in the majority of the studies, it was unclear in what time frame were the diagnostic biopsy or imaging performed in respect to the sample collection and the biomarker testing.

3. Results and Discussion

A PRISMA flow diagram demonstrating the search strategy and study selection criteria that were applied is shown in Figure 1.

Figure 1.

Figure 1

PRISMA Flow diagram of the search strategy and study selection.

The overall quality of the 49 selected and reviewed studies is illustrated in Figure 2.

Figure 2.

Figure 2

Graphical representation of the overall quality of the selected studies.

In Figure 2 it is evident that the majority of the studies (70%) had a low risk of bias in the Reference Standard domain, as the information on histological confirmation that samples originated from PDAC was specified. The unclear bias in this domain seen in approximately 30% of the studies was due to the absence of comparison of biomarkers with CA19-9. High risk of bias in the Index test (biomarker assay) was seen in 36% of studies and was associated with missing information on if the samples were analyzed in the blinded fashion. The lack of clarity, which was seen in the following 36% of the studies, was due to absence of robust statistical analysis of the data, i.e., splitting of the data into the training and the validation sets. Regarding patient selection criteria, around 20% of studies did not compare PDAC results to appropriate benign controls, leading to a high risk of bias. Around 20% of studies raised concerns about the applicability of the biomarkers for earlier PDAC detection, as they were not assessed in resectable stage I–II PDAC.

A graphical summary of the QUADAS-2 results with the descriptive score for each of the selected studies is presented in a tabular form in supplementary Appendix A, Table A1.

Table 2 summarizes the key findings from all 49 studies included in this review.

Table 2.

Key findings from included studies.

Reference Specimen
Type
Biomarker Clinical Setting Subjects Sensitivity (%) Specificity (%) AUC
Gold et al., 2010 [37] Serum PAM4 68 PDAC, 19 HC PDAC vs. HC 82.0 95.0 0.92 (0.84–0.97)
Joergensen et al., 2010 [38] Serum CA19-9
MMP-9
TIMP1
51 PDAC, 52 HC PDAC vs. HC 86.0
58.8
47.1
73.0
34.6
69.2
0.84 (0.77–0.92)
0.50 (0.39–0.61)
0.64 (0.53–0.74)
Marten et al., 2010 [39] Plasma siC3b 157 PDAC, 38 HC 2–4mo prior radiologically defined recurrence 54.0 94.0 0.85
siC3b 0–2mo prior radiologically defined recurrence 62.0 94.0 0.84
Brand et al., 2011 [17] Serum CA19-9
CA19-9 + ICAM-1 + OPG
CA19-9 + CEA +TIMP-1
160 PDAC,
74 BPD,
107 HC
TS:
PDAC vs. HC
PDAC vs. BPD
PDAC vs. HC
57,2
88.0
76.0
90.0
90.0
90.0
0.83 (0.81–0.86)
0.93 (0.91–0.95)
0.86
CA19-9
CA19-9 + ICAM-1 + OPG
CA19-9 + CEA +TIMP-1
CA19-9
173 PDAC,
70 BPD,
120 HC
VS:
PDAC vs. BPD
PDAC vs. HC
PDAC vs. BPC
PDAC vs. BPC
56.4
78.0
71.2
52.1
90.0
94.1
88.6
90.2
0.82 (0.78–0.86)
0.91 (0.88–0.95)
0.83 (0.88–0.89)
0.78 (0.74–0.83)
Park et al., 2012 [21] Serum Cathepsin D
MMP-7
CA19-9
CA19-9 + Cathepsin D + MMP-7
109 PDAC,
40 HC, 30 CP
TS: PDAC vs. HC + CP 54.0
72.0
74.0
88.0
80.0
80.0
80.0
80.0
0.67
0.81
0.84
0.90 (p = 0.002)
Cathepsin D
MMP-7
CA19-9
CA19-9 + Cathepsin D + MMP-7
129 PDAC,
74 HC, 72 CP
VS: PDAC vs. HC + CP 53.0
65.0
78.0
89.0
79.0
79.0
84.0
77.0
0.65
0.77
0.88
0.91 (p = 0.002)
Capello et al., 2013 [40] Serum EZR-autoantibody 69 PDAC, 46 CP, 60 HC, 12 Aim, 50 Non-PDAC PDAC vs. HC + CP + Aim 93.2 75.5 0.90
PDAC vs. non-PDAC cancer 94.9 96.4 0.99
Gold et al., 2013 [41] Serum PAM4
CA19-9
PAM4 + CA19-9
298 PDAC, 120 BPD, 50 CP PDAC vs. BPD 74.0
77.0
84.0
85.0
73.0
83.0
0.87 (p = 0.0001)
0.85 (p = 0.0257)
0.91
PAM4
CA19-9
PAM4 + CA19-9
PDAC vs. CP 74.0
77.0
84.0
86.0
68.0
82.0
0.87 (p = 0.0001)
0.84 (p = 0.0073)
0.91
Kobayashi et al., 2013 [42] Serum Diagnostic Model *
CA19-9
CEA
Diagnostic Model *
CA19-9
CEA
43 PDAC,
42 HC
TS: PDAC vs. HC 86.0
62.8
44.2
88.1
100.0
97.6
0.93 (0.86–0.97)
0.82 (0.70–0.90)
0.80 (0.69–0.88)
9 PDAC (stage 0-IIB),
41 HC, 23 CP
VS: PDAC stage 0-IIB vs. HC + CP 77.8
55.6
44.4
78.1
85.9
79.7
0.76 (0.66–0.86)
0.79 (0.68–0.88)
0.67 (0.55–0.76)
Li et al., 2013 [43] Serum CA19-9
miR-1290
miR-146a
miR-484
41 PDAC,
19 HC,
35 CP
PC vs. HC 71.0
88.0
78.0
76.0
90.0
84.0
79.0
63.0
0.86
0.96 (0.91–1.00)
0.82 (0.71–0.92)
0.78
CA19-9
miR-1290
miR-146a
miR-484
PDAC vs. CP 71.0
83.0
73.0
75.0
63.0
69.0
80.0
69.0
0.71
0.81 (0.71–0.91)
0.78 (0.68–0.89)
0.75
Zhao et al., 2013 [44] Serum miR -192 70 PDAC, 40 HC PDAC vs. HC 76.0 55.0 0.63 (0.51–0.75)
Chung et al., 2014 [45] Serum sCD40L
CA19-9
CEA
55 PDAC, 30 CP,
30 HC
VS: PDAC vs. CP vs. HC 80
80
68.9
85.5
72.7
60
0.88
0.78
0.70
Lee et al., 2014 [46] Serum CFB
CA19-9
CFB + CA19-9
41 PDAC, 44 HC, 12 CP, 31 HCC, 22 CC, 35 GC PDAC vs. non-PDAC 73.1
80.4
90.1
97.9
70.0
97.2
0.958 (0.956–0.959)
0.833 (0.829–0.837)
0.986 (p < 0.001)
Nolen et al., 2014 [47] Serum CA19-9
CA19-9 + CEA
CA19-9 + CEA + Cyfra 21-1
343 PDAC, 227 HC 1–12 months Pre-diagnostic PDAC vs. HC 25.7
26.7
32.4
95.0
95.0
95.0
0.680
0.67
0.69
CA19-9
CA19-9 + CEA
CA19-9 + CEA + Cyfra 21-1
12–35 months Pre-diagnostic PDAC vs. HC 17.2
28.1
29.7
95.0
95.0
95.0
0.63
0.66
0.66
Ren et al., 2014 [48] Serum IL-11p 44 PDAC, 30 HC PDAC vs. HC 97.7 70.0 0.901 (p < 0.001)
Schultz et al., 2014 [49] Serum Index 1 (miR-145, -150, -223, -636)
Index 2 (miR-26b, -34a, -122, -126, -145, -150, -223, -505, -636, -885.5p)
CA19-9
Index 1 + CA19-9
Index 2 + CA19-9
143 PDAC,
18 CP, 69 HC
DC:
PDAC vs. HC + CP
85.0 73.0 0.88 (0.85–0.92)
85.0
88.0
85.0
85.0
86.0
92.0
93.0
97.0
0.93 (0.89–0.96)
0.87 (0.82–0.92)
0.88 (0.83–0.93)
0.95 (0.92–0.98)
Index 1
Index 2
CA19-9
Index 1 + CA19-9
Index 2 + CA19-9
180 PDAC,
199 HC
TS:
PDAC vs.
HC
85.0
85.0
86.0
85.0
85.0
64.0
85.0
99.0
95.0
98.0
0.86 (0.82–0.90)
0.93 (0.89–0.96)
0.90 (0.87–0.94)
0.93 (0.90–0.96)
0.97 (0.95–0.98)
Index 1
Index 2
CA19-9
Index 1 + CA19-9
Index 2 + CA19-9
86 PDAC, 7 CP,
44 HC
VS:
PDAC vs. HC + CP
85.0
85.0
79.0
85.0
85.0
45.0
51.0
88.0
88.0
86.0
0.83 (0.76–0.90)
0.81 (0.73–0.87)
0.89 (0.83–0.95)
0.93 (0.88–0.97)
0.92 (0.87–0.96)
Yang et al., 2014 [50] Stool miR-21
miR-155
miR -216
miR-216 + miR-21+ miR-155
30 PDAC, 15 HC PDAC vs. HC 90.0
76.7
86.7
83.3
66.7
73.3
60.0
83.3
0.80 (0.68–0.92)
0.72 (0.58–0.86)
0.73 (0.60–0.86)
0.87 (0.77–0.96)
Zhang et al., 2014 [51] Serum CA19-9 + Albumin + CRP + IL-8
CA19-9
CA19-9 + Albumin + CRP + IL-8
CA19-9
163 PDAC (77 Early stage I-II),
109 BC,
200 HC
All stage PDAC vs. HC
All stage PDAC vs. HC
Early stage PDAC vs. HC
Early stage PDAC vs. HC
99.4
80.6
96.1
72.7
90.0
90.0
90.0
90.0
0.98 (0.97–1.00)
0.85 (0.80–0.90)
0.97 (0.95–1.00)
0.83 (0.75–0.90)
CA19-9 + CO2 +CRP + IL-6
CA19-9
CA19-9 + CO2 +CRP + IL-6
CA19-9
All stage PDAC vs. BC
All stage PDAC vs. BC
Early stage PDAC vs. BC
Early stage PDAC vs. BC
74.2
53.4
75.3
40.3
90.0
90.0
90.0
90.0
0.89 (0.86–0.93)
0.75 (0.69–0.81)
0.87 (0.82–0.93)
0.69 (0.61–0.78)
Debernardi et al., 2015 [52] Urine miR-143
miR-223
miR-30e
miR-143 + miR-30e
6 PDAC (stage I),
26 HC
Stage I PDAC vs. HC 83.3
83.3
83.3
83.3
88.5
76.9
80.8
96.2
0.86 (0.70–1.00)
0.80 (0.59–1.00)
0.85 (0.67–1.00)
0.92 (0.79–1.00)
Han et al., 2015 [53] Serum Dickkopf-1 (DKK1)
CA19-9
140 PDAC, (62 Early stage I-II),
48 HC,
18 BPT,
26 CP
PDAC vs. HC + BPT + CP 89.3
73.6
79.4
83.7
0.92 (0.88–0.95)
0.85 (0.80–0.90)
Dickkopf-1 (DKK1)
CA19-9
PDAC vs. BPT + CP 89.3
73.6
72.7
81.8
0.89 (0.83–0.95)
0.83 (0.77–0.89)
Dickkopf-1 (DKK1)
CA19-9
Early-PDAC vs. HC + BPT + CP 85.5
64.5
79.3
83.7
0.89 (0.84–0.94)
0.81 (0.74–0.89)
Dickkopf-1 (DKK1)
CA19-9

Early-PDAC vs. BPT + CP
85.5
64.5
72.7
81.8
0.85 (0.78–0.93)
0.78 (0.70–0.87)
Melo et al., 2015 [54] Serum GPC1 + crExos
CA19-9
190 PDAC, 100 HC,
26 BPD
DS:
PDAC vs. HC + BPD
100.0
76.8
100.0
64.3
1.00 (0.99–1.00)
0.74 (0.70–0.83)
GPC1 + crExos
GPC1 (ELISA)
56 PDAC, 20 HC,
6 BPD
VS:
PDAC vs. HC + BPD
100.0
82.1
100.0
75.0
1.00 (0.96–1.00)
0.78 (0.68–0.87)
Radon et al., 2015 [55] Urine LYVE1
REG1A
TFF1
LYVE1 + REG1A + TFF1 + (Creatinine +Age)
143 PDAC (stage I-IV),
59 HC
TS: PDAC vs. HC 76.9
62.2
72.7
76.9
88.1
94.9
59.3
89.8
0.85 (0.80–0.90)
0.82 (0.77–0.88)
0.69 (0.61–0.77)
0.89 (0.85–0.94)
LYVE1
REG1A
TFF1
LYVE1 + REG1A + TFF1 + (Creatinine +Age)
56 PDAC (stage I-II), 61 HC 67.9
75.0
78.6
82.1
91.8
68.9
52.5
88.5
0.84 (0.77–0.91)
0.75 (0.66–0.84)
0.70 (0.60–0.79)
0.90 (0.84–0.96)
LYVE1 + REG1A + TFF1 + (Creatinine +Age) 49 PDAC (stage I-IV), 28 HC VS: PDAC vs. HC 75.5 100 0.92 (0.84–1.00)
LYVE1 + REG1A + TFF1 + (Creatinine +Age) 56 PDAC (stage I-II), 61 HC 80.0 76.9 0.93 (0.84–1.00)
Plasma CA19-9
Panel (LYVE1 + REG1A + TFF1)
Panel + Plasma CA19-9
71 PDAC (stage I-II), 28 HC Exploratory Comparison 83.1
93.0
94.4
92.9
92.9
100
0.88 (0.81–0.95)
0.97 (0.95–1.00)
0.99 (0.98–1.00)
Ankeny et al., 2016 [56] Serum CTCs and KRAS
mutation analysis
72 PDAC,
28 non-adenocarcinoma
PDAC vs. non-adenocarcinoma 78.0 96.4 0.87 (0.80–0.94)
Guo et al., 2016 [57] Serum DTNBP1
CA19-9
250 PDAC, 70 CP, 80 BBO, 150 HC PDAC vs. BBO + CP + HC 81.9
76.3
84.7
52.5
0.85 (0.81–0.89)
0.74 (0.70–0.78)
DTNBP1
CA19-9
PDAC vs. CP
73.9
66.3
78.9
73.2
0.80 (0.75–0.86)
0.69 (0.63–0.75)
DTNBP1
CA19-9
PDAC vs. BBO 82.3
53.8
84.0
49.4
0.85 (0.80–0.89)
0.59 (0.53–0.65)
Henriksen et al., 2016 [58] Plasma (Model13): age >65+ BMP3+ RASSF1A+ BNC1+ MESTv2+ TFPI2+ APC+ SFRP1 +
SFRP2
95 PDAC, 97 CP,
27 “screened negative”
PDAC vs. screened negative + CP 73.0 83.0 0.86 (0.81–0.91)
Sogawa et al., 2016 [59] Serum C4BPA
CA19-9
CEA
C4BPA + CA19-9
66 PDAC,
40 HC,
20 CP
PDAC vs. HC + CP 67.3
71.2
34.6
86.4
95.4
95.4
95.4
95.4
0.86 (p < 0.001)
0.85
0.77
0.93
C4BPA
CA19-9
CEA
18 PDAC (stage I-II),
40 HC,
20 CP
PDAC stage I-II vs. HC + CP 50.0
22.2
22.2
95.4
95.4
95.4
0.91 (p < 0.001)
0.74
0.87
Yoneyama et al., 2016 [60] Serum CA19-9
IGFBP2
IGFBP3
38 PDAC (stage I-II),
65 HC
Stage I-II PDAC vs. HC 60.5
68.4
76.3
92.3
67.7
70.7
0.84 (0.75–0.93)
0.71 (0.60–0.81)
0.77 (0.67–0.86)
Balasenthil et al., 2017 [61] Plasma CA19-9 55 PDAC (stage IA/ IB-IIA), 61HC Stage IA/ IB-IIA vs. HC 71.0 61.0 0.74 (0.64–0.84)
TNC + TFP1 + CA19-9 55 PDAC (stage IA/ IB-IIA), 62 CP Stage IA/ IB-IIA vs. CP 73.0 82.0 0.79 (0.70–0.87)
CA19-9
TNC + TFP1 + CA19-9
71.0
73.0
44.0
71.0
0.69 (0.58–0.79)
0.75 (0.65–0.84)
Yang et al., 2017 [62] Plasma EGFR
EPCAM
HER2
MUC1
GPC1
WNT2
GRP94
B7-H3
EGFR + EPCAM + HER2 + MUC1
EGFR + EPCAM + GPC1 + WNT2
EGFR + EPCAM + MUC1 + GPC1 + WNT2
EGFR + EPCAM + HER2 + MUC1 + GPC1 + WNT2
22 PDAC, 10 HC TS:
PDAC vs. HC
73
73
59
36
55
77
73
50
91
100
100
100
100
100
90
100
60
90
70
100
100
100
100
100
0.90 (0.79–1)
0.88 (0.77–0.99)
0.72 (0.55–0.89)
0.66 (0.48–0.84)
0.48 (0.28–0.67)
0.84 (0.71–0.96)
0.73 (0.55–0.90)
0.75 (0.58–0.93)
0.99 (0.97–1)
1.0
1.0
1.0
EGFR
EPCAM
HER2
MUC1
GPC1
WNT2
GRP94
EGFR + EPCAM + HER2 + MUC1
EGFR + EPCAM + GPC1 + WNT2
EGFR + EPCAM + MUC1 + GPC1 + WNT2
EGFR + EPCAM + HER2 + MUC1 + GPC1 + WNT2
22 PDAC, 8 CP, 5 BPD,
8 other abdominal indications
VS:
PDAC vs. CP vs. BPD vs. other abdominal indications
59
45
59
36
82
64
55
86
82
86
95
76
95
85
90
52
76
71
86
90
81
81
67 (51–81)
70 (54–83)
72 (56–85)
63 (47–77)
67 (51–81)
70 (54–83)
63 (47–77)
86 (72–95)
86 (72–95)
84 (69–93)
88 (75–96)
Capello et al., 2017 [63] Serum/
Plasma
CA19-9
TIMP1 + LRG1 + CA19-9
TIMP1 + LRG1 + CA19-9 (“OR” Rule)
CA19-9
39 early stage PDAC,
82 HC
TS: early stage PDAC vs. HC 53.8
66.7
72.6
84.9
95.0
95.0
95.0
95.0
0.82 (0.74–0.91)
0.89 (0.82–0.96)
0.88 (0.81–0.96)
0.95 (0.92–0.98)
CA19-9
TIMP1 + LRG1 + CA19-9
73 early stage PDAC,
60 HC
VS: early stage PDAC vs. HC 84.9
28.8
95.0
95.0
0.96 (0.89–1.00)
0.82 (0.74–0.91)
Hussein et al., 2017 [64] Serum miR-22-3p
miR-642b-3p
miR-885-5p
CA19-9
35 PDAC (33 early stage, 2 late stage)
15 HC
PDAC vs. HC 97.1
100
100
91.4
93.3
100
100
100
0.94 (p < 0.001)
1.00 (p < 0.001)
1.00 (p < 0.001)
0.92 (p < 0.001)
Kaur et al., 2017 [65] Serum MUC5AC
CA19-9
70 PDAC (stage I or II),
43 CP,
35 HC,
30 BC
Early PDAC vs. HC 83.0
56.0
80.0
95.0
0.87 (0.79–0.95)
0.72 (0.59–0.84)
MUC5AC
CA19-9
Early PDAC vs. BC 67.0
48.0
87.0
89.0
0.85 (0.76–0.93)
0.71 (0.59–0.83)
MUC5AC
CA19-9
Early PDAC vs. CP 83.0
48.0
77.0
86.0
0.84 (0.76–0.92)
0.62 (0.50–0.74)
MUC5AC
CA19-9
MUC5AC + CA19-9
PDAC vs. HC + BC + CP 89.0
79.0
83.0
70.0
43.0
83.0
0.88 (0.83–0.93)
0.61 (0.54–0.68)
0.91 (0.86–0.95)
Kim et al., 2017 [66] Plasma CA19-9 (≥55)
THBS2 (36ng/mL cut-off)
CA19-9 + THBS2
58 (stage I-II, phase 2a),
80 HC
PDAC stage I or II vs. HC 69.0
33.0
74.1
100
96.0
96.3
0.85 (0.80–0.89)
0.83 (0.78–0.89)
0.95 (0.92–0.98)
CA19-9
THBS2
CA19-9 + THBS2
88 (stage I-II, phase 2b),
140 HC
77.7
58.4
88.3
98.6
93.6
92.9
0.83 (0.79–0.97)
0.89 (0.85–0.92)
0.96 (0.94–0.98)
Lai et al., 2017 [67] Plasma CA19-9
miR-10b
miR-21
miR-30c
miR-106b
miR-20a
miR-181a
miR-483
miR-let7a
miR-122
29 PDAC, 6 HC PDAC vs. HC 86.0
100.0
86.0
100.0
97.0
93.0
97.0
66.0
93.0
100.0
100.0
100.0
100.0
100.0
100.0
100.0
100.0
67.0
100.0
67.0
0.92 (p < 0.001)
1.00 (p < 0.001)
0.95 (p < 0.001)
1.00 (p < 0.001)
0.98 (p < 0.001)
0.99 (p < 0.001)
0.97 (p < 0.001)
0.67 (p = 0.20)
0.99 (p < 0.001)
0.89 (p = 0.003)
Park et al., 2017 [68] Serum LRG1 + TTR + CA19-9
CA19-9
LRG1 + TTR + CA19-9
CA19-9
LRG1 + TTR + CA19-9
CA19-9
LRG1 + TTR + CA19-9
CA19-9
LRG1 + TTR + CA19-9
CA19-9
80 PDAC (50 stage I-II) (29 CA19-9 negative PDAC), 68 HC, 21 BPD, 52 Thyroid Ca, 52 Breast Ca, 45 Colorectal Ca) PDAC vs. HC + BPC (n = 89)
PDAC stage I-II vs. HC + BPC (n = 89)
PDAC vs. Other Cancers (n = 149)
PDAC vs. BPD
CA19-9 negative PDAC (n = 29) vs. HC + BPC
82.5
72.5
76.0
64.0
82.5
72.5
82.5
72.5
51.7
24.1
92.1
88.8
92.1
88.8
83.9
87.9
85.7
81.0
92.1
88.8
0.93 (p < 0.01)
0.83
0.91 (p < 0.01)
0.79
0.90 (p < 0.001)
0.80
0.90
0.81
0.83 (p < 0.001)
0.52
Schott et al., 2017 [69] Serum HYAL2
Methylation
82 PDAC, 191 HC
60 PDAC (stage I-II),
191 HC
PDAC vs. HC
PDAC stage I-II vs. HC
75.6
66.7
93.7
95.3
0.92 (0.88–0.96)
0.93 (0.89–0.98)
Arasaradnam
et al., 2018 [70]
Urine Volatile organic compounds 4 PDAC stage I, 5 stage IIA, 35 stage IIB, 24 stage III, 12 stage IV,
81 HC
TS: PDAC vs. HC
VS:
PDAC vs. HC
PDAC stage I -II vs. HC
PDAC stage I -II vs. PDAC stage III-IV
0.91
0.90
0.91
0.82
0.83
0.81
0.78
0.89
0.92 (0.88–0.96)
0.92 (0.85–0.98)
0.89 (0.83–0.94)
0.92 (0.86–0.97)
Dong et al., 2018 [71] Serum CA19-9
POSTN
CA242
CA19-9 + POSTN
CA19-9 + CA242
POSTN+ CA242
CA19-9 + POSTN+ CA242
30 PDAC (early stage),
68 PDAC (late stage),
32 BPC,
37 HC,
27 PDAC (CA19-9 negative)
TS:
HC vs. early PDAC
96.7
70.0
81.1
93.3
90.0
83.3
96.7
83.8
75.7
81.1
94.6
94.6
86.5
94.6
0.94 (0.86–0.99)
0.78 (0.66–0.87)
0.89 (0.79–0.95)
0.97 (0.90–1.00)
0.96 (0.88–0.99)
0.90 (0.80–0.96)
0.98 (0.90–1.00)
CA19-9
POSTN
CA242
CA19-9 + POSTN
CA19-9 + CA242
POSTN+ CA242
CA19-9 + POSTN+ CA242
BPC vs. all PDAC 85.7
64.3
58.1
84.7
75.5
67.4
84.7
81.3
87.5
87.5
90.6
90.6
96.9
90.6
0.88 (0.82–0.93)
0.81 (0.74–0.88)
0.78 (0.70–0.85)
0.93 (0.88–0.97)
0.89 (0.83–0.94)
0.87 (0.80–0.92)
0.94 (0.88–0.97)
CA19-9
POSTN
CA242
CA19-9 + POSTN
CA19-9 + CA242
POSTN+ CA242
CA19-9 + POSTN+ CA242
38 PDAC (early stage),
77 PDAC (late stage),
43 BPC;
37 HC,
29 PDAC (CA19-9 negative)
BPC vs. early PDAC 86.7
53.3
83.3
96.7
90.0
56.7
96.7
81.3
87.5
62.5
75.0
78.1
96.9
75.0
0.88 (0.77–0.95)
0.74 (0.61–0.84)
0.78 (0.66–0.88)
0.90 (0.80–0.96)
0.90 (0.79–0.96)
0.80 (0.68–0.89)
0.92 (0.82–0.97)
CA19-9
POSTN
CA242
CA19-9 + POSTN
CA19-9 + CA242
POSTN+ CA242
CA19-9 + POSTN+ CA242
VS:
HC vs. early PDAC
86.8
63.2
57.9
86.8
86.8
79.0
92.1
94.6
78.4
100
97.3
97.3
94.6
97.3
0.94 (0.86–0.98)
0.78 (0.66–0.86)
0.83 (0.73–0.91)
0.95 (0.88–0.99)
0.97 (0.90–1.00)
0.92 (0.84–0.97)
0.98 (0.92–1.00)
CA19-9
POSTN
CA242
CA19-9 + POSTN
CA19-9 + CA242
POSTN+ CA242
CA19-9 + POSTN+ CA242
BPC vs. all PDAC 84.4
77.4
60.0
83.5
77.4
84.4
80.0
81.4
79.1
93.0
93.0
88.4
83.7
97.7
0.88 (0.82–0.93)
0.82 (0.76–0.88)
0.79 (0.72–0.85)
0.92 (0.87–0.96)
0.90 (0.84–0.94)
0.89 (0.83–0.93)
0.93 (0.88–0.96)
CA19-9
POSTN
CA242
CA19-9 + POSTN
CA19-9 + CA242
POSTN+ CA242
CA19-9 + POSTN+ CA242
BPC vs. early PDAC 86.8
65.8
57.9
65.8
76.3
76.3
83.6
79.1
79.1
93.0
93.0
93.0
86.1
88.4
0.87 (0.78–0.93)
0.72 (0.61–0.82)
0.77 (0.66–0.85)
0.84 (0.75–0.92)
0.92 (0.83–0.97)
0.84 (0.74–0.91)
0.90 (0.81–0.96)
Guo et al., 2018 [72] Serum SNHG15 171 PDAC, 59 HC PDAC vs. HC 68.3 89.6 0.73 (p < 0.01)
Lewis et al., 2018 [73] Whole blood, plasma, serum GPC1 + CD63 20 PDAC
6 BPD
PDAC vs. BPD 81 70 0.79 (0.99–1.00)
Mellby et al., 2018 [74] Plasma Panel of 29 biomarkers 15 PDAC stage I,
75 stage II, 15 stage III, 38 stage IV
57 CP,
20 IPMN,
219 HC
TS 2:
PDAC stage I-II vs. HC
95 94 0.96 (0.94–0.98)
VS (USA cohort):
PDAC stage I-II vs. HC
93 95 0.96 (0.94–0.98)
Traeger et al., 2018 [75] Serum miRNA-205
CA19-9
miRNA-205 +CA19-9
47 PDAC,
16 CP,
5 IPMN,
17 BPC,
17 HC
PDAC vs. non-PDAC 0.643
0.810
0.867
0.684
0.768
0.933
0.70 (0.548–0.789)
0.79 (0.698–0.887)
0.89 (0.782–0.995)
Zhou et al., 2018 [76] Serum GPC1
CA19-9
156 PDAC,
20 BPT,
16 CP,
163 HC
PDAC vs. HC + BPT + CP 76.92
82.69
70.85
93.97
0.80 (0.749–0.841)
0.91 (0.868–0.947)
GPC1
CA19-9
PDAC vs. HC 76.92
82.69
70.55
97.55
0.81 (0.763–0.856)
0.91 (0.875–0.953)
GPC1
CA19-9
Early PDAC vs. HC + BPT + CP 68.06
79.17
70.85
93.97
0.76 (0.695–0.816)
0.88 (0.816–0.946)
GPC1
CA19-9
Early PDAC vs. HC 68.06
79.17
70.55
97.55
0.77 (0.705–0.830)
0.89 (0.824–0.953)
Berger et al., 2019 [77] Plasma CA19-9
THBS2
cfDNA
CA19-9 + THBS2
THBS2 + CA19-9 + cfDNA
52 PDAC,
15 IPMN,
32 CP
TS:
PDAC vs. IPMN vs. CP
55
41
32–86 1
73
41–86 1
91
96
70–100 1
91
78–96 1
0.80
0.73
0.90
0.87
0.94
CA19-9
THBS2
cfDNA
CA19-9 + THBS2
THBS2 + CA19-9 + cfDNA
VS:
PDAC vs. IPMN vs. CP
63
50
43–80 1
80
50–93 1
96
96
79–96 1
96
92–96 1
0.70
0.63
0.81
0.78
0.88
Eissa et al., 2019 [78] Plasma ADAMTS1 39 PDAC,
95 HC
PDAC vs. HC 87.2 95.8 0.91 (0.77–0.90)
BNC1 64.1 93.7 0.79 (0.63–0.78)
ADAMTS1 and/or BNC1 97.4 91.6 0.95 (0.71–0.86)
Fahrmann et al., 2019 [79] Plasma AcSperm+ DAS + indole-derivative+ LysoPC(18:0) + LysoPC(20:3) 29 PDAC,
10 HC
TS:
PDAC vs. HC
69.0 99.0 0.90 (0.818–0.989)
AcSperm+ DAS + indole-derivative+ LysoPC(18:0) + LysoPC(20:3) 39 Resectable PDAC,
82 HC
VS:
PDAC vs. HC
66.7 43.3 0.89 (0.828–0.996)
Indole-derivative
LysoPC(18:0)
LysoPC(20:3)
AcSperm
DAS
23.1
51.3
48.7
33.3
51.3
11.3
26.3
11.3
27.5
27.5
0.73 (0.631–0.822)
0.84 (0.764–0.920)
0.84 0.757–0.925)
0.76 (0.659–0.852)
0.80 (0.712–0.890)
Yu et al., 2019 [80] Plasma d-signature: EV long RNA (FGA, KRT19, HIST1H2BK, ITIH2, MARCH2, CLDN1, MAL2 and TIMP1) 284 PDAC, 100 CP, 117 HC PDAC vs. CP vs. HC
d-signature with CA19-9
93.68 91.57 0.936 (0.889–0.983)
Takahashi et al., 2019 [81] Serum Circulating EV-encapsulated HULC 20 PDAC, 22 IPMN, 21 HC PDAC vs. IPMN vs. HC 80 92.1 0.92
Wei et al., 2019 [82] Plasma Vimetin-positive CTCs 100 PDAC, 16 IPMN, 30 HC PDAC vs. IPMN vs. HC 65 100 0.968
Yang et al., 2020 [83] Plasma EV miRNAs and mRNAs, cfDNA, ccfDNA KRAS G12D/V/R mutations and CA19-9 30 CP + BPC, 49 PDAC, 57 HC PDAC vs. non-PDAC vs. HC 88 95 0.95 (p= 0.103)

Abbreviations: Aim: autoimmune diseases; BBO: benign biliary obstruction; BBP: benign biliary pathology; BCT: benign cystic tumor; BPD: benign pancreatic disease; BPT: benign pancreatic tumor; CC: cholangiocarcinoma; ccfDNA: circulating cell-free DNA; cf: circulating free; CP: chronic pancreatitis; CTC: circulating tumor cell; DC: discovery cohort; EV: extracellular vesicles; GC: gastric cancer; HC: healthy control; HCC: hepatocellular carcinoma; HULC: highly upregulated in liver cancer; IPMN: intraductal papillary mucinous neoplasm; PC: prospective cohort; PDAC: pancreatic ductal adenocarcinoma; TS: training set; VS: validation set. Note: 1 Depending on the concentration of cfDNA.

The studies summarized in Table 2 were all aimed at earlier PDAC detection; however, around 20% of them did not analyze their biomarkers in resectable stage I–II samples. While the paucity of earliest stage I samples is a recognized problem in the PDAC field, this was surprising, considering the critical importance of diagnostic stage shift. Selection of the relevant control population is also of the essence, as PDAC is an uncommon cancer, which dictates the need to assess the putative biomarkers in high-risk groups [1,84,85], a criterion which was not satisfied in 20% of the studies. It also requires the high accuracy of any potential future biomarker assay with at least 88% SN and 85% SP if the test is to be cost-effective [86].

A third of the reviewed studies did not include a comparison of their biomarkers to CA19-9, which was unexpected considering that CA19-9 is the most commonly measured biomarker in PDAC patients. Very few biomarkers were conclusively superior to CA19-9 and in the majority of studies where their combination was tested, the accuracy of PDAC detection was superior to either biomarker alone. For example, Dong et al. [71] described the panel of serum biomarkers comprising CA19-9, POSTN and CA242, which was superior to CA19-9 alone in differentiating between PDAC and both healthy controls (AUC of 0.98, 92.1% SN and 97.3% SP) and benign pancreatic conditions (AUC of 0.93, 80% SN and 97.7% SP), albeit with somewhat lower AUC of 0.90 and a decrease in SP to 88% in resectable PDAC. In the study of Berger et al. [77], CA19-9 combined with THBS2 and cfDNA in PDAC vs. non-PDAC patients showed an increase in AUC from 0.70 to 0.78, with an increased SN and SP of 80% and 96%, respectively. A study by Fahrmann et al. [79] combined a five-metabolite panel (acetylspermidine, diacetylspermine, an indole-derivative and two lysophosphatidylcholines) with a previously validated protein panel comprising CA19-9, TIMP1 and LRG1, achieving AUC of 0.924 (95% CI 0.864–0.983). Recently, another panel (FGA, KRT19, HIST1H2BK, ITIH2, MARCH2, CLDN1, MAL2 and TIMP1) obtained by plasma extracellular vesicle long RNA profiling (d-signature), successfully differentiated PDAC from CP and healthy controls with AUC of 0.936, and both SN and SP > 90%; furthermore, when combined with CA19-9, the signature showed improved AUC of 0.964 (95% CI: 0.943–0.984) [80]. Traeger et al., reported that miRNA-205 combined with CA19-9 resulted in higher SN and SP in comparison of PDAC vs. benign specimens (86.7% SN and 93.3% SP) than either of the biomarkers alone [75].

The absolute SN and SP values for PDAC detection using glypican-1 (GPC1) in circulating exosomes when PDAC samples were compared to healthy and benign samples was reported by Melo et al. [54]. However, several subsequent studies failed to support these findings [62,73,87,88], while Zhou et al. [76] demonstrated that combining GPC1 and CA19-9 showed 92.31% SN at 65.83% SP for distinguishing healthy, chronic pancreatitis and benign pancreatic tumors from PDAC. Regardless of the underlying reasons, these conflicting results highlight the critical importance of independent validation of any proposed biomarkers.

The above study [54] and the more recent studies indicate the “expansion” of the biomarker field, moving from the “traditional” DNA, RNA and protein biomarkers to novel, versatile analytes and their combinations, such as non-coding RNAs, epigenetic markers, lipids and metabolites, as well as circulating tumor cells and extracellular vesicles (EV) [88]. For example, Yang et al. [83] performed a multi-parametric analysis of blood tumor-associated EV miRNA and mRNA, circulating cell-free DNA concentration and KRAS G12D/V/R mutations with CA19-9, and demonstrated their higher accuracy for PDAC staging (84%) than imaging alone (accuracy = 64%; P < 0.05). Furthermore, recent advances in computer science, machine learning and artificial intelligence (AI) have given rise to the emerging field of bioinformatics and computational biology which allow analyses of large collections of biological data [89]. While AI was mostly utilized for the prediction of risk/diagnosis based on health records or abdominal imaging [1,90,91], it also shows a great potential for in silico discovery of putative novel biomarkers. For example, Khatri and Bhasin [92] used transcriptomics-based meta-analysis of tissue and blood samples combined with machine learning to identify a nine-gene panel (IFI27, ITGB5, CTSD, EFNA4, GGH, PLBD1, HTATIP2, IL1R2 and CTSA) that differentiated PDAC and healthy controls with 92% SN and 90% SP. Moreover, this panel also discriminated PDAC from chronic pancreatitis and early precursor lesions in non-malignant tissue and peripheral blood. Chung et al. [93] used probe electrospray ionization mass spectrometry (PESI-MS) and a machine learning approach to analyze peripheral blood samples and achieved an accuracy of 92.1% in healthy vs. PDAC (90.8% SN, 91.7% SP). The combination of PESI-MS profiles with age and CA19-9 increased the accuracy for detection of stage I and II PDAC to 92.9% (81.2% SN, 96.8% SP) [40]. This demonstrates that the access to richly annotated patients’ health records will enable the construction of novel PDAC prediction tools such as the one developed by Muhammad et al. [90]. Combining such prediction tools with biofluid biomarkers now opens up promising new avenues and likely a fruitful approach to identify asymptomatic patients at increased risk of developing PDAC.

Very few studies explored the effectiveness of their proposed biomarkers in pre-diagnostic samples from asymptomatic patients. Although such samples are not readily available, these studies are essential for determining how early in the latency period the biomarkers can be detected [40,47,94,95,96,97,98,99,100,101]. Nolen et al. [47] interrogated the large prospective Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial serum samples to detect eight biomarkers: CEA-related cell adhesion molecule 1 (CEACAM1) and prolactin (PRL) were detectable up to 35 months before PDAC diagnosis; CA19-9, carcinoembryonic antigen (CEA), neuron-specific enolase (NSE) and beta-human chorionic gonadotropin (b-HCG) up to 24 months; and CA125 and interleukin 8 (IL-8) up to 12 months prior PDAC diagnosis. In the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) serum samples, a decrease in circulating TSP-1 levels up to 24 months prior to PDAC diagnosis was described by Jenkinson et al. [97], and O’Brien et al. demonstrated that CA19-9 could be detected in such pre-diagnostic PDAC samples with 95% SP and 68% SN up to 1 year and 53% SN up to 2 years prior to PDAC diagnosis [98]. A three-biomarker panel comprising Erb-B2 receptor tyrosine kinase 2 (ERBB2), estrogen receptor 1 (ESR1) and tenascin C (TNC) was analyzed in 87 pre-diagnostic plasma samples from Women’s Health Initiative (WHI) collected up to 4 years before diagnosis and achieved AUC of 0.71 when combined with CA19-9 [100]. Recently, the analysis of 1196 proteins in longitudinal plasma samples from the Institute for Systems Biology’s 100K Wellness project identified several markers, including three that were observed in PDAC: CEA cell adhesion molecule 5 (CEACAM5) was expressed at high levels 26.5 months pre-diagnosis, while calcitonin related polypeptide alpha (CALCA) and delta1 like homolog (DLK1) were predating PDAC diagnosis for around 17 months [101]. More exciting projects such as this are needed and should be actively encouraged.

While performing this review, we encountered a number of hurdles, particularly noticeable in the way the studies were reported. Easier reviewing of published resources would be facilitated, and the extraction of the relevant information simplified, if a consensus set of standards for the reporting of biomarker studies were utilized. In addition to QUADAS-2, several of such recommendations and guidelines exist: BRISQ (Biospecimen Reporting for Improved Study Quality) [102] provides recommendations for reporting details about the interrogated biospecimens; the Standards for Reporting of Diagnostic Accuracy Studies (STARD) [103] was developed to improve the completeness and transparency of the reports; and Reporting Recommendations for Tumour Marker Prognostic Studies (REMARK) [104] and Consolidated Standards of Reporting Trials (CONSORT Statement) [105] are used to improve the overall quality of tumor markers in the prognostic studies and randomized trials [104,105] . The latter is the final step in establishing the clinical utility of the biomarker, i.e., increased survival due to earlier diagnosis achieved by biomarker testing. Interestingly, only studies published in high-impact factors journals followed any of these recommendations [49,54,66,74,80].

In addition to the standardized way of reporting, a standardized pathway for early detection and diagnosis is also needed. Such pathway has recently been summarized in the updated Cancer Research UK (CRUK) roadmap, which aims to consolidate the current diverse and fragmented research activities, in line with the future vision to detect 75% of cancers at stage I-II by 2028 [106]. A roadmap also illustrates a long way from biomarker discovery to its implementation, with a number of hurdles encountered at every step in biomarker pipeline, from initial biomarker discovery, its quantification, verification and assay optimization to finally biomarker validation and commercialization, as comprehensively discussed previously [107,108,109]. While biomarker discovery is usually well funded and results straightforward to report, validation, which is a necessary step prior to commercialization, is time-consuming and expensive process, with scarce funding available. The transition from discovery to the clinical utility of any biomarker is therefore a cumbersome process, akin to the implementation of novel therapeutic [110].

It is not surprising thus that, despite a large number of candidate biomarkers, very few are close to clinical implementation. Based on the accuracy of 95% of serum biomarker signature published by Mellby et al. [74] and using their proprietary antibody platform, Immunovia is now developing the commercial assay IMMRay™ PanCan-d, which is currently being further validated in the prospective studies [111]. Our urinary biomarker panel comprising REG1B, LYVE1, TFF1 and the affiliated PancRISK score [112,113] are now being validated in a prospective study UroPanc [114] . A multi-analyte blood test that simultaneously evaluates the levels of eight cancer proteins and the presence of cancer gene mutations from circulating DNA, CancerSEEK®, screens for eight common cancers, including PDAC [115], and has already been commercialized. GRAIL is advocating its own Galleri test, which is based on cfDNA methylation signal and can detect over 50 different cancers [116]. Both platforms, however, suffer from lower SN in detecting stage I cancers, and there is a legitimate concern that the tests might be less specific in real-world conditions, where comorbidities may increase the risk of a false-positive result [117].

4. Conclusions

In summary, our systematic review demonstrates the current progress in the biomarker field and highlights several promising non-invasive PDAC biomarkers. Most of these, however, still require further validation prior to being deemed appropriate for translation into the clinical setting. All future studies should aim to improve methodological quality and the way of reporting. Novel biomarkers that have shown promising results should be further investigated on a larger number of specimens, as well as in a pre-diagnostic and prospective setting, to further demonstrate their real clinical utility in earlier detection of pancreatic adenocarcinoma.

Appendix A

Table A1.

Graphical summary of the QUADAS-2 scores for each of the 49 studies.

Nr. Study Risk of Bias Applicability Concerns Score
Patient Selection Index Test Reference Standard Patient Selection Index Test Reference Standard
1 Gold et al., 2010 [37] ? ? Low
2 Joergensen et al., 2010 [38] ? Low
3 Marten et al., 2010 [39] ? ? High
4 Brand et al., 2011 [17] ? Low
5 Park et al., 2012 [21] ? Low
6 Capello et al., 2013 [40] Low
7 Gold et al., 2013 [41] ? Low
8 Kobayashi et al., 2013 [42] Low
9 Li et al., 2013 [43] Low
10 Zhao et al., 2013 [44] ? High
11 Chung et al., 2014 [45] Low
12 Lee et al., 2014 [46] Low
13 Nolen et al., 2014 [47] Low
14 Ren et al., 2014 [48] Low
15 Schultz et al., 2014 [49] ? Low
16 Yang et al., 2014 [50] ? ? High
17 Zhang et al., 2014 [51] ? Low
18 Debernardi et al., 2015 [52] ? ? High
19 Han et al., 2015 [53] Low
20 Melo et al., 2015 [54] ? Low
21 Radon et al., 2015 [55] ? Low
22 Ankeny et al., 2016 [56] ? ? High
23 Guo et al., 2016 [57] Low
24 Henriksen et al., 2016 [58] ? Low
25 Sogawa et al., 2016 [59] Low
26 Yoneyama et al., 2016 [60] ? Low
27 Balasenthil et al., 2017 [61] Low
28 Yang et al., 2017 [62] ? ? Low
29 Capello et al., 2017 [63] ? Low
30 Hussein et al., 2017 [64] High
31 Kaur et al., 2017 [65] Low
32 Kim et al., 2017 [66] Low
33 Lai et al., 2017 [67] High
34 Park et al., 2017 [68] Low
35 Schott et al., 2017 [69] ? High
36 Arasaradnam et al., 2018 [70] ? ? High
37 Dong et al., 2018 [71] ? Low
38 Guo et al., 2018 [72] ? High
39 Mellby et al., 2018 [74] ? Low
40 Traeger et al., 2018 [75] Low
41 Zhou et al., 2018 [76] ? High
42 Berger et al., 2019 [77] Low
43 Eissa et al., 2019 [78] ? Low
44 Fahrmann et al., 2019 [79] Low
45 Lewis et al., 2019 [73] ? ? ? High
46 Yu et al., 2019 [80] Low
47 Takahashi et al., 2019 [81] ? ? High
48 Wei et al., 2019 [82] ? Low
49 Yang et al., 2020 [83] ? Low

Low Risk; High Risk; ? Unclear Risk.

Author Contributions

Conceptualization, V.S., G.B. and T.C.-J.; methodology, G.B., V.S. and T.C.-J.; writing and editing, G.B., V.S., D.J. and T.C.-J.; and supervision, T.C.-J. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflict of interest.

Footnotes

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Pereira S.P., Oldfield L., Ney A., Hart P.A., Keane M.G., Pandol S.J., Li D., Greenhalf W., Jeon C.Y., Koay E.J., et al. Early detection of pancreatic cancer. Lancet Gastroenterol. Hepatol. 2020;5:698–710. doi: 10.1016/S2468-1253(19)30416-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020. CA Cancer J. Clin. 2020;70:7–30. doi: 10.3322/caac.21590. [DOI] [PubMed] [Google Scholar]
  • 3.Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. [DOI] [PubMed] [Google Scholar]
  • 4.da Costa W.L., Jr., Oluyomi A.O., Thrift A.P. Trends in the Incidence of Pancreatic Adenocarcinoma in All 50 United States Examined Through an Age-Period-Cohort Analysis. JNCI Cancer Spectr. 2020;4:pkaa033. doi: 10.1093/jncics/pkaa033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Rawla P., Sunkara T., Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J. Oncol. 2019;10:10–27. doi: 10.14740/wjon1166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Lin Q.J., Yang F., Jin C., Fu D.L. Current status and progress of pancreatic cancer in China. World J. Gastroenterol. 2015;21:7988–8003. doi: 10.3748/wjg.v21.i26.7988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Shen G.Q., Aleassa E.M., Walsh R.M., Morris-Stiff G. Next-Generation Sequencing in Pancreatic Cancer. Pancreas. 2019;48:739–748. doi: 10.1097/MPA.0000000000001324. [DOI] [PubMed] [Google Scholar]
  • 8.Bortesi L., Pesci A., Bogina G., Castelli P., Zamboni G. Ductal Adenocarcinoma of the Pancreas. Surg. Pathol. Clin. 2011;4:487–521. doi: 10.1016/j.path.2011.03.007. [DOI] [PubMed] [Google Scholar]
  • 9.CancerResearchUK Pancreatic Cancer Statistics 2015–2017. [(accessed on 15 July 2020)]; Available online: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/pancreatic-cancer.
  • 10.Pancreatic Cancer UK Pancreatic Cancer Statistics. [(accessed on 2 July 2020)]; Available online: https://www.pancreaticcancer.org.uk/what-we-do/media-centre/pancreatic-cancer-statistics.
  • 11.Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2018. CA Cancer J. Clin. 2018;68:7–30. doi: 10.3322/caac.21442. [DOI] [PubMed] [Google Scholar]
  • 12.Huang L., Jansen L., Balavarca Y., Molina-Montes E., Babaei M., van der Geest L., Lemmens V., Van Eycken L., De Schutter H., Johannesen T.B., et al. Resection of pancreatic cancer in Europe and USA: An international large-scale study highlighting large variations. Gut. 2019;68:130. doi: 10.1136/gutjnl-2017-314828. [DOI] [PubMed] [Google Scholar]
  • 13.Shimizu Y., Yasui K., Matsueda K., Yanagisawa A., Yamao K. Small carcinoma of the pancreas is curable: New computed tomography finding, pathological study and postoperative results from a single institute. J. Gastroenterol. Hepatol. 2005;20:1591–1594. doi: 10.1111/j.1440-1746.2005.03895.x. [DOI] [PubMed] [Google Scholar]
  • 14.Ishikawa O., Ohigashi H., Imaoka S., Nakaizumi A., Uehara H., Kitamura T., Kuroda C. Minute carcinoma of the pancreas measuring 1 cm or less in diameter—Collective review of Japanese case reports. Hepatogastroenterology. 1999;46:8–15. [PubMed] [Google Scholar]
  • 15.Yachida S., Jones S., Bozic I., Antal T., Leary R., Fu B., Kamiyama M., Hruban R.H., Eshleman J.R., Nowak M.A., et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467:1114–1117. doi: 10.1038/nature09515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Ghaneh P., Costello E., Neoptolemos J.P. Biology and management of pancreatic cancer. Gut. 2007;56:1134–1152. doi: 10.1136/gut.2006.103333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Brand R.E., Nolen B.M., Zeh H.J., Allen P.J., Eloubeidi M.A., Goldberg M., Elton E., Arnoletti J.P., Christein J.D., Vickers S.M., et al. Serum biomarker panels for the detection of pancreatic cancer. Clin. Cancer Res. 2011;17:805–816. doi: 10.1158/1078-0432.CCR-10-0248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Chan A., Diamandis E.P., Blasutig I.M. Strategies for discovering novel pancreatic cancer biomarkers. J. Proteom. 2013;81:126–134. doi: 10.1016/j.jprot.2012.09.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Tempero M.A., Uchida E., Takasaki H., Burnett D.A., Steplewski Z., Pour P.M. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res. 1987;47:5501–5503. [PubMed] [Google Scholar]
  • 20.FDA FDA 510K Summary. [(accessed on 20 February 2021)]; Available online: https://www.accessdata.fda.gov/cdrh_docs/pdf2/K020566.pdf.
  • 21.Park H.-D., Kang E.-S., Kim J.-W., Lee K.-T., Lee K.H., Park Y.S., Park J.-O., Lee J., Heo J.S., Choi S.H., et al. Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma. Proteomics. 2012;12:3590–3597. doi: 10.1002/pmic.201200101. [DOI] [PubMed] [Google Scholar]
  • 22.Ritts R.E., Pitt H.A. CA 19-9 in pancreatic cancer. Surg. Oncol. Clin. N. Am. 1998;7:93–101. doi: 10.1016/S1055-3207(18)30286-2. [DOI] [PubMed] [Google Scholar]
  • 23.Duffy M.J., van Dalen A., Haglund C., Hansson L., Klapdor R., Lamerz R., Nilsson O., Sturgeon C., Topolcan O. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur. J. Cancer. 2003;39:718–727. doi: 10.1016/S0959-8049(02)00811-0. [DOI] [PubMed] [Google Scholar]
  • 24.Ballehaninna U.K., Chamberlain R.S. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J. Gastrointest. Oncol. 2012;3:105–119. doi: 10.3978/j.issn.2078-6891.2011.021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Passerini R., Cassatella M.C., Boveri S., Salvatici M., Radice D., Zorzino L., Galli C., Sandri M.T. The pitfalls of CA19-9: Routine testing and comparison of two automated immunoassays in a reference oncology center. Am. J. Clin. Pathol. 2012;138:281–287. doi: 10.1309/AJCPOPNPLLCYR07H. [DOI] [PubMed] [Google Scholar]
  • 26.Duffy M.J., Sturgeon C., Lamerz R., Haglund C., Holubec V.L., Klapdor R., Nicolini A., Topolcan O., Heinemann V. Tumor markers in pancreatic cancer: A European Group on Tumor Markers (EGTM) status report. Ann. Oncol. 2010;21:441–447. doi: 10.1093/annonc/mdp332. [DOI] [PubMed] [Google Scholar]
  • 27.Herlyn M., Steplewski Z., Herlyn D., Koprowski H. Colorectal carcinoma-specific antigen: Detection by means of monoclonal antibodies. Proc. Natl. Acad. Sci. USA. 1979;76:1438–1442. doi: 10.1073/pnas.76.3.1438. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Hotakainen K., Tanner P., Alfthan H., Haglund C., Stenman U.H. Comparison of three immunoassays for CA 19-9. Clin. Chim. Acta. 2009;400:123–127. doi: 10.1016/j.cca.2008.10.033. [DOI] [PubMed] [Google Scholar]
  • 29.Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am. J. Gastroenterol. 1990;85:350–355. [PubMed] [Google Scholar]
  • 30.Stern P., Friedecky B., Bartos V., Bezdickova D., Vavrova J., Uhrova J., Rozprimova L., Zima T., Palicka V. Comparison of different immunoassays for CA 19-9. Clin. Chem. Lab. Med. 2001;39:1278–1282. doi: 10.1515/CCLM.2001.205. [DOI] [PubMed] [Google Scholar]
  • 31.Goh S.K., Gold G., Christophi C., Muralidharan V. Serum carbohydrate antigen 19-9 in pancreatic adenocarcinoma: A mini review for surgeons. ANZ J. Surg. 2017;87:987–992. doi: 10.1111/ans.14131. [DOI] [PubMed] [Google Scholar]
  • 32.Jain K.K. The Handbook of Biomarkers. Humana Press; Totowa, NJ, USA: 2010. [Google Scholar]
  • 33.Young M.R., Wagner P.D., Ghosh S., Rinaudo J.A., Baker S.G., Zaret K.S., Goggins M., Srivastava S. Validation of Biomarkers for Early Detection of Pancreatic Cancer: Summary of The Alliance of Pancreatic Cancer Consortia for Biomarkers for Early Detection Workshop. Pancreas. 2018;47:135–141. doi: 10.1097/MPA.0000000000000973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PloS Med. 2009;6:e1000097. doi: 10.1371/journal.pmed.1000097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Whiting P.F., Rutjes A.W., Westwood M.E., Mallett S., Deeks J.J., Reitsma J.B., Leeflang M.M., Sterne J.A., Bossuyt P.M. QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann. Intern. Med. 2011;155:529–536. doi: 10.7326/0003-4819-155-8-201110180-00009. [DOI] [PubMed] [Google Scholar]
  • 36.Whiting P., Rutjes A.W., Reitsma J.B., Bossuyt P.M., Kleijnen J. The development of QUADAS: A tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med. Res. Methodol. 2003;3:25. doi: 10.1186/1471-2288-3-25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Gold D.V., Goggins M., Modrak D.E., Newsome G., Liu M., Shi C., Hruban R.H., Goldenberg D.M. Detection of early-stage pancreatic adenocarcinoma. Cancer Epidemiol. Biomark. Prev. 2010;19:2786–2794. doi: 10.1158/1055-9965.EPI-10-0667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Joergensen M.T., Brunner N., De Muckadell O.B.S. Comparison of Circulating MMP-9, TIMP-1 and CA19-9 in the Detection of Pancreatic Cancer. Anticancer Res. 2010;30:587–592. [PubMed] [Google Scholar]
  • 39.Marten A., Buchler M.W., Werft W., Wente M.N., Kirschfink M., Schmidt J. Soluble iC3b as an Early Marker for Pancreatic Adenocarcinoma Is Superior to CA19.9 and Radiology. J. Immunother. 2010;33:219–224. doi: 10.1097/CJI.0b013e3181bed29f. [DOI] [PubMed] [Google Scholar]
  • 40.Capello M., Cappello P., Linty F.C., Chiarle R., Sperduti I., Novarino A., Salacone P., Mandili G., Naccarati A., Sacerdote C., et al. Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models. J. Hematol. Oncol. 2013;6:67. doi: 10.1186/1756-8722-6-67. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Gold D.V., Gaedcke J., Ghadimi B.M., Goggins M., Hruban R.H., Liu M.L., Newsome G., Goldenberg D.M. PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma. Cancer. 2013;119:522–528. doi: 10.1002/cncr.27762. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Kobayashi T., Nishiumi S., Ikeda A., Yoshie T., Sakai A., Matsubara A., Izumi Y., Tsumura H., Tsuda M., Nishisaki H., et al. A novel serum metabolomics-based diagnostic approach to pancreatic cancer. Cancer Epidemiol. Biomark. Prev. 2013;22:571–579. doi: 10.1158/1055-9965.EPI-12-1033. [DOI] [PubMed] [Google Scholar]
  • 43.Li A., Yu J., Kim H., Wolfgang C.L., Canto M.I., Hruban R.H., Goggins M. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin. Cancer Res. 2013;19:3600–3610. doi: 10.1158/1078-0432.CCR-12-3092. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Zhao C., Zhang J., Zhang S., Yu D., Chen Y., Liu Q., Shi M., Ni C., Zhu M. Diagnostic and biological significance of microRNA-192 in pancreatic ductal adenocarcinoma. Oncol. Rep. 2013;30:276–284. doi: 10.3892/or.2013.2420. [DOI] [PubMed] [Google Scholar]
  • 45.Chung H.W., Lim J.B. Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma. J. Transl. Med. 2014;12:102. doi: 10.1186/1479-5876-12-102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Lee M.J., Na K., Jeong S.K., Lim J.S., Kim S.A., Song S.Y., Kim H., Hancock W.S., Paik Y.K. Identification of human complement factor B as a novel biomarker candidate for pancreatic ductal adenocarcinoma. J. Proteome Res. 2014;13:4878–4888. doi: 10.1021/pr5002719. [DOI] [PubMed] [Google Scholar]
  • 47.Nolen B.M., Brand R.E., Prosser D., Velikokhatnaya L., Allen P.J., Zeh H.J., Grizzle W.E., Huang Y., Lomakin A., Lokshin A.E. Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study. PLoS ONE. 2014;9:e94928. doi: 10.1371/journal.pone.0094928. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Ren C., Chen Y., Han C., Fu D., Chen H. Plasma interleukin-11 (IL-11) levels have diagnostic and prognostic roles in patients with pancreatic cancer. Tumour Biol. 2014;35:11467–11472. doi: 10.1007/s13277-014-2459-y. [DOI] [PubMed] [Google Scholar]
  • 49.Schultz N.A., Dehlendorff C., Jensen B.V., Bjerregaard J.K., Nielsen K.R., Bojesen S.E., Calatayud D., Nielsen S.E., Yilmaz M., Holländer N.H., et al. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. JAMA. 2014;311:392–404. doi: 10.1001/jama.2013.284664. [DOI] [PubMed] [Google Scholar]
  • 50.Yang J.Y., Sun Y.W., Liu D.J., Zhang J.F., Li J., Hua R. MicroRNAs in stool samples as potential screening biomarkers for pancreatic ductal adenocarcinoma cancer. Am. J. Cancer Res. 2014;4:663–673. [PMC free article] [PubMed] [Google Scholar]
  • 51.Zhang P.J., Zou M., Wen X.Y., Gu F., Li J., Liu G.X., Dong J.X., Deng X.X., Gao J., Li X.L., et al. Development of serum parameters panels for the early detection of pancreatic cancer. Int. J. Cancer. 2014;134:2646–2655. doi: 10.1002/ijc.28584. [DOI] [PubMed] [Google Scholar]
  • 52.Debernardi S., Massat N.J., Radon T.P., Sangaralingam A., Banissi A., Ennis D.P., Dowe T., Chelala C., Pereira S.P., Kocher H.M., et al. Noninvasive urinary miRNA biomarkers for early detection of pancreatic adenocarcinoma. Am. J. Cancer Res. 2015;5:3455–3466. [PMC free article] [PubMed] [Google Scholar]
  • 53.Han S.X., Zhou X., Sui X., He C.C., Cai M.J., Ma J.L., Zhang Y.Y., Zhou C.Y., Ma C.X., Varela-Ramirez A., et al. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer. Oncotarget. 2015;6:19907–19917. doi: 10.18632/oncotarget.4529. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Melo S.A., Luecke L.B., Kahlert C., Fernandez A.F., Gammon S.T., Kaye J., LeBleu V.S., Mittendorf E.A., Weitz J., Rahbari N., et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015;523:177–182. doi: 10.1038/nature14581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Radon T.P., Massat N.J., Jones R., Alrawashdeh W., Dumartin L., Ennis D., Duffy S.W., Kocher H.M., Pereira S.P., Guarner L., et al. Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma. Clin. Cancer Res. 2015;21:3512–3521. doi: 10.1158/1078-0432.CCR-14-2467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Ankeny J.S., Court C.M., Hou S., Li Q., Song M., Wu D., Chen J.F., Lee T., Lin M., Sho S., et al. Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer. Br. J. Cancer. 2016;114:1367–1375. doi: 10.1038/bjc.2016.121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Guo X., Lv X., Fang C., Wang F., Wang D., Zhao J., Ma Y., Xue Y., Bai Q., Yao X., et al. Dysbindin as a novel biomarker for pancreatic ductal adenocarcinoma identified by proteomic profiling. Int. J. Cancer. 2016;139:1821–1829. doi: 10.1002/ijc.30227. [DOI] [PubMed] [Google Scholar]
  • 58.Henriksen S.D., Madsen P.H., Larsen A.C., Johansen M.B., Drewes A.M., Pedersen I.S., Krarup H., Thorlacius-Ussing O. Cell-free DNA promoter hypermethylation in plasma as a diagnostic marker for pancreatic adenocarcinoma. Clin. Epigenetics. 2016;8:1–12. doi: 10.1186/s13148-016-0286-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Sogawa K., Takano S., Iida F., Satoh M., Tsuchida S., Kawashima Y., Yoshitomi H., Sanda A., Kodera Y., Takizawa H., et al. Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein α-chain (C4BPA) by quantitative proteomic analysis using tandem mass tags. Br. J. Cancer. 2016;115:949–956. doi: 10.1038/bjc.2016.295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Yoneyama T., Ohtsuki S., Honda K., Kobayashi M., Iwasaki M., Uchida Y., Okusaka T., Nakamori S., Shimahara M., Ueno T., et al. Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics. PLoS ONE. 2016;11:e0161009. doi: 10.1371/journal.pone.0161009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Balasenthil S., Huang Y., Liu S., Marsh T., Chen J., Stass S.A., KuKuruga D., Brand R., Chen N., Frazier M.L., et al. A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer. J. Natl. Cancer Inst. 2017;109 doi: 10.1093/jnci/djw341. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Yang K.S., Im H., Hong S., Pergolini I., del Castillo A.F., Wang R., Clardy S., Huang C.-H., Pille C., Ferrone S., et al. Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy. Sci. Transl. Med. 2017;9:eaal3226. doi: 10.1126/scitranslmed.aal3226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Capello M., Bantis L., Scelo G., Zhao Y., Dhillon D., Wang H., Abbruzzese J., Maitra A., Tempero M., Brand R., et al. Sequential validation of bloodbased protein biomarker candidates for early-stage pancreatic cancer; Proceedings of the 107th Annual Meeting of the American Association for Cancer Research, AACR 2016; New Orleans, LA, USA. 16–20 April 2016; [Google Scholar]
  • 64.Hussein N.A., Kholy Z.A., Anwar M.M., Ahmad M.A., Ahmad S.M. Plasma miR-22-3p, miR-642b-3p and miR-885-5p as diagnostic biomarkers for pancreatic cancer. J. Cancer Res. Clin. Oncol. 2017;143:83–93. doi: 10.1007/s00432-016-2248-7. [DOI] [PubMed] [Google Scholar]
  • 65.Kaur S., Smith L., Patel A., Menning M., Watley D., Malik S., Krishn S., Mallya K., Aithal A., Sasson A., et al. A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter Study. Am. J. Gastroenterol. 2017;112:172–183. doi: 10.1038/ajg.2016.482. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Kim J., Bamlet W.R., Oberg A.L., Chaffee K.G., Donahue G., Cao X.J., Chari S., Garcia B.A., Petersen G.M., Zaret K.S. Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers. Sci. Transl. Med. 2017;9:eaah5583. doi: 10.1126/scitranslmed.aah5583. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Lai X.Y., Wang M., McElyea S.D., Sherman S., House M., Korc M. A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer. Cancer Lett. 2017;393:86–93. doi: 10.1016/j.canlet.2017.02.019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Park J., Choi Y., Namkung J., Yi S.G., Kim H., Yu J., Kim Y., Kwon M.S., Kwon W., Oh D.Y., et al. Diagnostic performance enhancement of pancreatic cancer using proteomic multimarker panel. Oncotarget. 2017;8:93117–93130. doi: 10.18632/oncotarget.21861. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Schott S., Yang R.X., Stocker S., Canzian F., Giese N., Bugert P., Bergmann F., Strobel O., Hackert T., Sohn C., et al. HYAL2 methylation in peripheral blood as a potential marker for the detection of pancreatic cancer-a case control study. Oncotarget. 2017;8:67614–67625. doi: 10.18632/oncotarget.18757. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Arasaradnam R.P., Wicaksono A., O’Brien H., Kocher H.M., Covington J.A., Crnogorac-Jurcevic T. Noninvasive Diagnosis of Pancreatic Cancer Through Detection of Volatile Organic Compounds in Urine. Gastroenterology. 2018;154:485–487.e481. doi: 10.1053/j.gastro.2017.09.054. [DOI] [PubMed] [Google Scholar]
  • 71.Dong D., Jia L., Zhang L., Ma N., Zhang A., Zhou Y., Ren L. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer. Cancer Sci. 2018;109:2841–2851. doi: 10.1111/cas.13712. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Guo X.B., Yin H.S., Wang J.Y. Evaluating the diagnostic and prognostic value of long non-coding RNA SNHG15 in pancreatic ductal adenocarcinoma. Eur. Rev. Med. Pharm. Sci. 2018;22:5892–5898. doi: 10.26355/eurrev_201809_15917. [DOI] [PubMed] [Google Scholar]
  • 73.Lewis J.M., Vyas A.D., Qiu Y., Messer K.S., White R., Heller M.J. Integrated Analysis of Exosomal Protein Biomarkers on Alternating Current Electrokinetic Chips Enables Rapid Detection of Pancreatic Cancer in Patient Blood. ACS Nano. 2018;12:3311–3320. doi: 10.1021/acsnano.7b08199. [DOI] [PubMed] [Google Scholar]
  • 74.Mellby L.D., Nyberg A.P., Johansen J.S., Wingren C., Nordestgaard B.G., Bojesen S.E., Mitchell B.L., Sheppard B.C., Sears R.C., Borrebaeck C.A.K. Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer. J. Clin. Oncol. 2018;36:2887–2894. doi: 10.1200/JCO.2017.77.6658. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Michael Traeger M., Rehkaemper J., Ullerich H., Steinestel K., Wardelmann E., Senninger N., Abdallah Dhayat S. The ambiguous role of microRNA-205 and its clinical potential in pancreatic ductal adenocarcinoma. J. Cancer Res. Clin. Oncol. 2018;144:2419–2431. doi: 10.1007/s00432-018-2755-9. [DOI] [PubMed] [Google Scholar]
  • 76.Zhou C.Y., Dong Y.P., Sun X., Sui X., Zhu H., Zhao Y.Q., Zhang Y.Y., Mason C., Zhu Q., Han S.X. High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma. Cancer Med. 2018;7:5525–5533. doi: 10.1002/cam4.1833. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Berger A.W., Schwerdel D., Reinacher-Schick A., Uhl W., Algül H., Friess H., Janssen K.-P., König A., Ghadimi M., Gallmeier E., et al. A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer. Theranostics. 2019;9:1280–1287. doi: 10.7150/thno.29247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Eissa M.A.L., Lerner L., Abdelfatah E., Shankar N., Canner J.K., Hasan N.M., Yaghoobi V., Huang B., Kerner Z., Takaesu F., et al. Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood. Clin. Epigenetics. 2019;11:59. doi: 10.1186/s13148-019-0650-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Fahrmann J.F., Bantis L.E., Capello M., Scelo G., Dennison J.B., Patel N., Murage E., Vykoukal J., Kundnani D.L., Foretova L., et al. A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer. J. Natl. Cancer Inst. 2019;111:372–379. doi: 10.1093/jnci/djy126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Yu S., Li Y., Liao Z., Wang Z., Wang Z., Li Y., Qian L., Zhao J., Zong H., Kang B., et al. Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for the detection of pancreatic ductal adenocarcinoma. Gut. 2020;69:540–550. doi: 10.1136/gutjnl-2019-318860. [DOI] [PubMed] [Google Scholar]
  • 81.Takahashi K., Ota Y., Kogure T., Suzuki Y., Iwamoto H., Yamakita K., Kitano Y., Fujii S., Haneda M., Patel T., et al. Circulating extracellular vesicle-encapsulated HULC is a potential biomarker for human pancreatic cancer. Cancer Sci. 2020;111:98–111. doi: 10.1111/cas.14232. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Wei T., Zhang X., Zhang Q., Yang J., Chen Q., Wang J., Li X., Chen J., Ma T., Li G., et al. Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer. Cancer Lett. 2019;452:237–243. doi: 10.1016/j.canlet.2019.03.009. [DOI] [PubMed] [Google Scholar]
  • 83.Yang Z., LaRiviere M.J., Ko J., Till J.E., Christensen T., Yee S.S., Black T.A., Tien K., Lin A., Shen H., et al. A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and Staging of Pancreatic Ductal Adenocarcinoma. Clin. Cancer Res. 2020;26:3248–3258. doi: 10.1158/1078-0432.CCR-19-3313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Pang Y., Holmes M.V., Chen Z., Kartsonaki C. A review of lifestyle, metabolic risk factors, and blood-based biomarkers for early diagnosis of pancreatic ductal adenocarcinoma. J. Gastroenterol. Hepatol. 2019;34:330–345. doi: 10.1111/jgh.14576. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Becker A.E., Hernandez Y.G., Frucht H., Lucas A.L. Pancreatic ductal adenocarcinoma: Risk factors, screening, and early detection. World J. Gastroenterol. 2014;20:11182–11198. doi: 10.3748/wjg.v20.i32.11182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Ghatnekar O., Andersson R., Svensson M., Persson U., Ringdahl U., Zeilon P., Borrebaeck C.A. Modelling the benefits of early diagnosis of pancreatic cancer using a biomarker signature. Int. J. Cancer. 2013;133:2392–2397. doi: 10.1002/ijc.28256. [DOI] [PubMed] [Google Scholar]
  • 87.Frampton A.E., Prado M.M., López-Jiménez E., Fajardo-Puerta A.B., Jawad Z.A.R., Lawton P., Giovannetti E., Habib N.A., Castellano L., Stebbing J., et al. Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burden. Oncotarget. 2018;9:19006–19013. doi: 10.18632/oncotarget.24873. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88.Zhang W.H., Wang W.Q., Han X., Gao H.L., Li T.J., Xu S.S., Li S., Xu H.X., Li H., Ye L.Y., et al. Advances on diagnostic biomarkers of pancreatic ductal adenocarcinoma: A systems biology perspective. Comput. Struct. Biotechnol. J. 2020;18:3606–3614. doi: 10.1016/j.csbj.2020.11.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Almeida P.P., Cardoso C.P., de Freitas L.M. PDAC-ANN: An artificial neural network to predict pancreatic ductal adenocarcinoma based on gene expression. BMC Cancer. 2020;20:82. doi: 10.1186/s12885-020-6533-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Muhammad W., Hart G.R., Nartowt B., Farrell J.J., Johung K., Liang Y., Deng J. Pancreatic Cancer Prediction Through an Artificial Neural Network. Front. Artif. Intell. 2019;2:2. doi: 10.3389/frai.2019.00002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91.Marya N.B., Powers P.D., Chari S.T., Gleeson F.C., Leggett C.L., Abu Dayyeh B.K., Chandrasekhara V., Iyer P.G., Majumder S., Pearson R.K., et al. Utilisation of artificial intelligence for the development of an EUS-convolutional neural network model trained to enhance the diagnosis of autoimmune pancreatitis. Gut. 2020 doi: 10.1136/gutjnl-2020-322821. [DOI] [PubMed] [Google Scholar]
  • 92.Khatri I., Bhasin M.K. A Transcriptomics-Based Meta-Analysis Combined With Machine Learning Identifies a Secretory Biomarker Panel for Diagnosis of Pancreatic Adenocarcinoma. Front. Genet. 2020;11:572284. doi: 10.3389/fgene.2020.572284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Chung W.Y., Correa E., Yoshimura K., Chang M.C., Dennison A., Takeda S., Chang Y.T. Using probe electrospray ionization mass spectrometry and machine learning for detecting pancreatic cancer with high performance. Am. J. Transl. Res. 2020;12:171–179. [PMC free article] [PubMed] [Google Scholar]
  • 94.Sollie S., Michaud D.S., Sarker D., Karagiannis S.N., Josephs D.H., Hammar N., Santaolalla A., Walldius G., Garmo H., Holmberg L., et al. Chronic inflammation markers are associated with risk of pancreatic cancer in the Swedish AMORIS cohort study. BMC Cancer. 2019;19:858. doi: 10.1186/s12885-019-6082-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95.de la Fuente J., Sharma A., Chari S., Majumder S. Peripheral blood monocyte counts are elevated in the pre-diagnostic phase of pancreatic cancer: A population based study. Pancreatology. 2019;19:1043–1048. doi: 10.1016/j.pan.2019.10.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96.Cui Y., Shu X.O., Li H.L., Yang G., Wen W., Gao Y.T., Cai Q., Rothman N., Yin H.Y., Lan Q., et al. Prospective study of urinary prostaglandin E2 metabolite and pancreatic cancer risk. Int. J. Cancer. 2017;141:2423–2429. doi: 10.1002/ijc.31007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97.Jenkinson C., Elliott V.L., Evans A., Oldfield L., Jenkins R.E., O’Brien D.P., Apostolidou S., Gentry-Maharaj A., Fourkala E.O., Jacobs I.J., et al. Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus. Clin. Cancer Res. 2016;22:1734–1743. doi: 10.1158/1078-0432.CCR-15-0879. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98.O’Brien D.P., Sandanayake N.S., Jenkinson C., Gentry-Maharaj A., Apostolidou S., Fourkala E.O., Camuzeaux S., Blyuss O., Gunu R., Dawnay A., et al. Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: Implications for early disease detection. Clin. Cancer Res. 2015;21:622–631. doi: 10.1158/1078-0432.CCR-14-0365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99.Capello M., Bantis L.E., Scelo G., Zhao Y., Li P., Dhillon D.S., Patel N.J., Kundnani D.L., Wang H., Abbruzzese J.L., et al. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. J. Natl. Cancer Inst. 2017;109:djw266. doi: 10.1093/jnci/djw266. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100.Mirus J.E., Zhang Y., Li C.I., Lokshin A.E., Prentice R.L., Hingorani S.R., Lampe P.D. Cross-species antibody microarray interrogation identifies a 3-protein panel of plasma biomarkers for early diagnosis of pancreas cancer. Clin. Cancer Res. 2015;21:1764–1771. doi: 10.1158/1078-0432.CCR-13-3474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 101.Magis A.T., Rappaport N., Conomos M.P., Omenn G.S., Lovejoy J.C., Hood L., Price N.D. Untargeted longitudinal analysis of a wellness cohort identifies markers of metastatic cancer years prior to diagnosis. Sci. Rep. 2020;10:16275. doi: 10.1038/s41598-020-73451-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 102.Moore H.M., Kelly A.B., Jewell S.D., McShane L.M., Clark D.P., Greenspan R., Hayes D.F., Hainaut P., Kim P., Mansfield E.A., et al. Biospecimen reporting for improved study quality (BRISQ) Cancer Cytopathol. 2011;119:92–101. doi: 10.1002/cncy.20147. [DOI] [PubMed] [Google Scholar]
  • 103.Cohen J.F., Korevaar D.A., Altman D.G., Bruns D.E., Gatsonis C.A., Hooft L., Irwig L., Levine D., Reitsma J.B., de Vet H.C.W., et al. STARD 2015 guidelines for reporting diagnostic accuracy studies: Explanation and elaboration. BMJ Open. 2016;6:e012799. doi: 10.1136/bmjopen-2016-012799. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 104.Altman D.G., McShane L.M., Sauerbrei W., Taube S.E. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and elaboration. PLoS Med. 2012;9:e1001216. doi: 10.1371/journal.pmed.1001216. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 105.Schulz K.F., Altman D.G., Moher D. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332. doi: 10.1136/bmj.c332. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106.Crosby D., Lyons N., Greenwood E., Harrison S., Hiom S., Moffat J., Quallo T., Samuel E., Walker I. A roadmap for the early detection and diagnosis of cancer. Lancet Oncol. 2020;21:1397–1399. doi: 10.1016/S1470-2045(20)30593-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 107.Kunovsky L., Tesarikova P., Kala Z., Kroupa R., Kysela P., Dolina J., Trna J. The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer. Can. J. Gastroenterol. Hepatol. 2018;2018:5389820. doi: 10.1155/2018/5389820. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 108.Paulovich A.G., Whiteaker J.R., Hoofnagle A.N., Wang P. The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipeline. Proteom. Clin. Appl. 2008;2:1386–1402. doi: 10.1002/prca.200780174. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 109.Rifai N., Gillette M.A., Carr S.A. Protein biomarker discovery and validation: The long and uncertain path to clinical utility. Nat. Biotechnol. 2006;24:971–983. doi: 10.1038/nbt1235. [DOI] [PubMed] [Google Scholar]
  • 110.Root A., Allen P., Tempst P., Yu K. Protein Biomarkers for Early Detection of Pancreatic Ductal Adenocarcinoma: Progress and Challenges. Cancers. 2018;10:67. doi: 10.3390/cancers10030067. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 111.Immunovia. [(accessed on 25 August 2020)]; Available online: https://immunovia.com/about-us.
  • 112.Debernardi S., O’Brien H., Algahmdi A.S., Malats N., Stewart G.D., Plješa-Ercegovac M., Costello E., Greenhalf W., Saad A., Roberts R., et al. A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case–control study. PLoS Med. 2020;17:e1003489. doi: 10.1371/journal.pmed.1003489. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113.Blyuss O., Zaikin A., Cherepanova V., Munblit D., Kiseleva E.M., Prytomanova O.M., Duffy S.W., Crnogorac-Jurcevic T. Development of PancRISK, a urine biomarker-based risk score for stratified screening of pancreatic cancer patients. Br. J. Cancer. 2020;122:692–696. doi: 10.1038/s41416-019-0694-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 114.Clinicaltrials.gov Early Detection of Pancreatic Adenocarcinoma (PDAC) Using a Panel of Biomarkers (UroPanc) [(accessed on 3 March 2021)]; Available online: https://clinicaltrials.gov/ct2/show/NCT04449406.
  • 115.Cohen J.D., Li L., Wang Y., Thoburn C., Afsari B., Danilova L., Douville C., Javed A.A., Wong F., Mattox A., et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359:926–930. doi: 10.1126/science.aar3247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 116.Liu M.C., Oxnard G.R., Klein E.A., Swanton C., Seiden M.V., Consortium C. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann. Oncol. 2020;31:745–759. doi: 10.1016/j.annonc.2020.02.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 117.Killock D. CancerSEEK and destroy—A blood test for early cancer detection. Nat. Rev. Clin. Oncol. 2018;15:133. doi: 10.1038/nrclinonc.2018.21. [DOI] [PubMed] [Google Scholar]

Articles from Cancers are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES